ReviewJournal of biological engineering2026
Biodetection of Mycobacterium tuberculosis: nano-biosensors in detection; from principles to recent progresses.
Review in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) exerts profound detrimental impacts on global human populations. This infectious disease is primarily caused by Mycobacterium tuberculosis (MTB), a highly adapted pathogen that undergoes rapid genomic evolution, enabling it to acquire resistance to targeted antimicrobial agents. The emergence of chemotherapeutic resistance was first documented in the 1990s, with epidemiological data indicating that approximately 150,000 individuals succumb annually to multidrug-resistant (MDR) TB. For the detection of MTB, a variety of diagnostic approaches have been established. While culture-based methods remain the gold standard, molecular techniques offer superior reliability; however, they are costly and require specialized expertise. In the contemporary landscape of medical science, advancements in fundamental disciplines have facilitated the integration of nanotechnology into diagnostic applications, providing innovative materials for bacterial identification and infection diagnosis. Among these, nanoscale materials have been proposed as efficacious tools for MTB detection. Various nanoparticles, such as gold nanoparticles and graphene quantum dots, can be synthesized using different methodologies to enable precise identification of MTB in clinical specimens. On average, nanobiosensors achieve a limit of detection (LOD) of approximately 10³ colony-forming units per milliliter (CFU/mL), whereas magnetoelastic sensors exhibit LOD ranges from 10⁴ to 10⁹ CFU/mL. This review elucidates recent progress in nanobiosensor technologies for MTB detection, addresses associated challenges, reviews the current state of the field, and outlines prospective avenues for development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.